High Uptake and Series Completion of COVID-19 Vaccine at Community-Based Vaccination for Latinos With Limited English Proficiency

J Public Health Manag Pract. 2022 Nov-Dec;28(6):E789-E794. doi: 10.1097/PHH.0000000000001625. Epub 2022 Sep 5.

Abstract

Background: Despite the disproportionate impact of COVID-19 on Latinos, there were disparities in vaccination, especially during the early phase of COVID-19 immunization rollout.

Methods: Leveraging a community-academic partnership established to expand access to SARS-CoV2 testing, we implemented community vaccination clinics with multifaceted outreach strategies and flexible appointments for limited English proficiency Latinos.

Results: Between February 26 and May 7 2021, 2250 individuals received the first dose of COVID-19 vaccination during 18 free community events. Among them, 92.4% (95% confidence interval [CI], 91.2%-93.4%) self-identified as Hispanic, 88.7% (95% CI, 87.2%-89.9%) were limited English proficiency Spanish speakers, 23.1% (95% CI, 20.9%-25.2%) reported prior COVID-19 infection, 19.4% (95% CI, 16.9%-22.25%) had a body mass index of more than 35, 35.0% (95% CI, 32.2%-37.8%) had cardiovascular disease, and 21.6% (95% CI, 19.2%-24.0%) had diabetes. The timely second-dose completion rate was high (98.7%; 95% CI, 97.6%-99.2%) and did not vary by outreach method.

Conclusion: A free community-based vaccination initiative expanded access for Latinos with limited English proficiency at high risk for COVID-19 during the early phase of the immunization program in the US.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines*
  • BCG Vaccine
  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Hispanic or Latino
  • Humans
  • Influenza Vaccines*
  • Limited English Proficiency*
  • Measles-Mumps-Rubella Vaccine
  • Papillomavirus Vaccines*
  • RNA, Viral
  • Respiratory Syncytial Virus Vaccines*
  • SAIDS Vaccines*
  • SARS-CoV-2
  • Vaccination

Substances

  • AIDS Vaccines
  • BCG Vaccine
  • COVID-19 Vaccines
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Influenza Vaccines
  • Measles-Mumps-Rubella Vaccine
  • Papillomavirus Vaccines
  • RNA, Viral
  • Respiratory Syncytial Virus Vaccines
  • SAIDS Vaccines